Similar companies
Income Statement (USD)
| Q4 '24 | QoQ | |
|---|---|---|
| Operating expense | 14M | 5.2% |
| Net Income | -12M | 4.2% |
| EBITDA | -14M | 15.6% |
Balance Sheet (USD)
| Q4 '24 | QoQ | |
|---|---|---|
| Total Assets | 124M | 8.5% |
| Total Liabilities | 13M | 14.2% |
| Total Equity | 111M | 7.8% |
| Shares Outstanding | 85M | 0% |
Cash Flow (USD)
| Q4 '24 | QoQ | |
|---|---|---|
| Cash from operations | -12M | 82% |
| Cash from financing | 710,000 | 695.5% |
EPS
Financial Highlights for Anavex Life Sciences in Q4 '24
Operating Expenses for this period were 14M, showing a -5.2% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -12M, showing a -4.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -14M, showing a -15.6% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Anavex Life Sciences faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. A decline in EBITDA signals potential operational challenges or increased costs.
